20 terminated. 20 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Terminated 20 |
| Phase 1 | 4 | Terminated 4 |
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment - Chronic Urticaria, Idiopathic, Hidradenitis | Phase 2 | Terminated | InflaRx GmbH | 73 | 2025-01-02 | 2026-02-03 |
| A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials Briquilimab - Urticaria Chronic | Phase 2 | Terminated | Jasper Therapeutics, Inc. | 67 | 2024-11-26 | 2026-08-06 |
| A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines Briquilimab - Chronic Inducible Urticaria | Phase 1 / Phase 2 | Terminated | Jasper Therapeutics, Inc. | 27 | 2024-03-18 | 2025-10-08 |
| Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria Oral EP262, Placebo - Chronic Spontaneous Urticaria | Phase 2 | Terminated | Escient Pharmaceuticals, Inc | 113 | 2023-09-25 | 2025-12-19 |
| A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria Lirentelimab (AK002), Placebo - Chronic Spontaneous Urticaria | Phase 2 | Terminated | Allakos Inc. | 127 | 2022-10-26 | 2024-09-27 |
| Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II Deucrictibant low dose, Deucrictibant high dose, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 | Terminated | Pharvaris Netherlands B.V. | 34 | 2022-04-19 | 2026-08-17 |
| A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II KVD824, Placebo to KVD824 - Angioedema, Hereditary, Types I and II | Phase 2 | Terminated | KalVista Pharmaceuticals, Ltd. | 33 | 2021-11-18 | 2026-05-06 |
| Mepolizumab in Episodic Angioedema With Eosinophilia mepolizumab - Eosinophilia, Angioedema | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 5 | 2021-01-14 | 2024-04-16 |
| A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO) Benralizumab, Placebo and Benralizumab - Chronic Spontaneous Urticaria | Phase 2 | Terminated | AstraZeneca | 159 | 2020-10-27 | 2024-03-13 |
| Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) ATI-450 - Cryopyrin-Associated Periodic Syndrome | Phase 2 | Terminated | Aclaris Therapeutics, Inc. | 1 | 2020-10-23 | 2023-09-21 |
| Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 Conestat alfa - Coronavirus Infections | Phase 2 | Terminated | University Hospital, Basel, Switzerland | 80 | 2020-08-06 | 2021-11-09 |
| A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria LY3454738, Placebo - Chronic Spontaneous Urticaria | Phase 2 | Terminated | Eli Lilly and Company | 52 | 2019-11-15 | 2022-03-11 |
| A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study GDC-0853 - Urticaria | Phase 2 | Terminated | Genentech, Inc. | 31 | 2018-09-27 | 2020-09-25 |
| HL2351 CAPS Phase II Study HL2351 - Cryopyrin-Associated Periodic Syndromes (CAPS) | Phase 2 | Terminated | Handok Inc. | 8 | 2015-10-01 | 2017-01-04 |
| Efficacy and Safety of Miltefosine in Antihistamine Resistant Chronic Urticaria Miltefosine, Placebo - Chronic Urticaria | Phase 2 | Terminated | Marcus Maurer | 76 | 2008-09-01 | 2016-12-26 |
| Safety Study of Rituximab (Rituxan®) in Chronic Urticaria Rituximab - Urticaria | Phase 1 / Phase 2 | Terminated | Johns Hopkins University | 15 | 2006-01-01 | 2015-09-02 |
| Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease anakinra - Nervous System Malformations, Arthropathy, Neurogenic | Phase 1 / Phase 2 | Terminated | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 43 | 2003-09-01 | 2016-12-01 |
| A Study of the Use of Methotrexate in the Treatment of Chronic Idiopathic Urticaria Methotrexate (drug), placebo capsules - Urticaria | Phase 2 | Terminated | Barnsley Hospital | 3 | 2003-08-01 | 2016-02-19 |
| Efficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria Rupatadine Fumarate - URTICARIA | Phase 2 | Terminated | J. Uriach and Company | 248 | 2002-10-28 | 2022-02-18 |
| Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions UVA1 Irradiation, UVB Irradiation - Atopic Dermatitis, Psoriasis | Phase 1 / Phase 2 | Terminated | University of Michigan | 28 | 2000-08-01 | 2015-05-22 |
Chronic Urticaria (9) · Cryopyrin-Associated Periodic Syndromes (3) · Pruritus (3) · Angioedemas, Hereditary (2) · Hereditary Angioedema Types I and II (2) · Skin Diseases (2) · Alopecia (1) · Angioedema (1) · Arthropathy, Neurogenic (1) · COVID-19 (1) · Chronic Inducible Urticaria (1) · Congenital Abnormalities (1) · Coronavirus Infections (1) · Cytokine Release Syndrome (1)
Hypersensitivity (20) · Hypersensitivity, Immediate (20) · Skin and Connective Tissue Diseases (20) · Immune System Diseases (19) · Skin Diseases, Vascular (19) · Skin Diseases (18) · Pathological Conditions, Signs and Symptoms (14) · Pathologic Processes (13) · Chronic Disease (12) · Disease Attributes (12) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Cardiovascular Diseases (4) · Signs and Symptoms (4)
AK002 (1) · Interleukin 1 Receptor Antagonist Protein (1) · Methotrexate (1) · Pharmaceutical Preparations (1) · Rituximab (1) · Therapeutics (1) · benralizumab (1) · conestat alfa (1) · fenebrutinib (1) · mepolizumab (1) · miltefosine (1)
Jasper Therapeutics, Inc. (2) · Aclaris Therapeutics, Inc. (1) · Allakos Inc. (1) · AstraZeneca (1) · Barnsley Hospital (1) · Eli Lilly and Company (1) · Escient Pharmaceuticals, Inc (1) · Genentech, Inc. (1) · Handok Inc. (1) · InflaRx GmbH (1) · J. Uriach and Company (1) · Johns Hopkins University (1) · KalVista Pharmaceuticals, Ltd. (1) · Marcus Maurer (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (14) · Germany (10) · Poland (6) · Bulgaria (4) · Canada (3) · France (2) · Italy (2) · South Korea (2) · Spain (2) · United Kingdom (2) · Australia (1) · Austria (1) · Brazil (1) · Czechia (1) · Georgia (1)
Chin Lee, MD, MPH (1) · Clifton O. Bingham, III, MD (1) · David Gordon (1) · John J Voorhees, MD (1) · Marc Riedl, MD (1) · Markus Magerl, MD (1) · Michael Osthoff, PD Dr. med. (1) · Paneez Khoury, M.D. (1) · Raphaela T Goldbach-Mansky, M.D. (1)
PMID 12384926, PMID 15201414, PMID 15334472, PMID 16899778, PMID 17478385, PMID 18645136, PMID 22294344, PMID 25223501, PMID 27143789, PMID 28118536, PMID 33397449, PMID 37951310, PMID 37965347, PMID 41865746
2018 (1), 2019 (1), 2023 (1), ZIAAR041138-08 (1)